
Testosterone Screening and Cardiovascular Safety in TRAVERSE
Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.
In this episode, ‘Testosterone Screening and Cardiovascular Safety in TRAVERSE,’ expert urologists explore why testosterone deserves a place among routine health markers and how TRAVERSE changed the cardiovascular conversation.
Testosterone may be one of the most telling biomarkers of men’s health, yet it remains one of the least routinely measured. Helen L. Bernie, DO, MPH, points to its associations with mortality, cardiovascular disease, diabetes, and bone loss. She questions why guidelines stop short of recommending screening while thyroid testing remains routine despite similar evidence gaps. She stresses that screening is not the same as treating, since a low result opens the door to identifying reversible contributors such as obesity, sleep apnea, and medications. Amy Pearlman, MD, adds that a simple blood test could be a practical way to bring more men into regular contact with health care.
Mohit Khera, MD, MBA, then walks through the history behind the TRAVERSE trial, from early observational data linking low testosterone to cardiac events to a handful of flawed studies suggesting harm from treatment. He explains how those studies prompted a label warning and an FDA-mandated trial. Ultimately, the trial showed no increase in major adverse cardiovascular events. The warning was removed in 2025, though Khera doubts a trial of this scale will be repeated.
Abraham Morgentaler, MD, addresses skeptics who question whether transdermal results apply to injections or pellets. He notes consistent findings across other randomized trials, and that every formulation delivers the same bioidentical molecule. Because testosterone is a naturally occurring hormone, he argues, the formulation question comes down to convenience, response, and achieved levels rather than safety.
Clinicians can counsel men that the cardiovascular question has been answered by rigorous data, and that a low testosterone level warrants evaluation rather than dismissal, the experts conclude.
The next episode in this series, ‘Blood Pressure and Age-Related Hypogonadism Label Changes,’ features the panelists discussing the strengthened class-wide blood pressure warning and the FDA’s move away from excluding age-related hypogonadism.
Related to this article








